Business Context and Reporting Period
Company: Niagen Bioscience, Inc. (NAGE)
Filing Type: Form 8-K (Current Report)
Report Date: August 4, 2026
Reporting Period: The filing announces earnings for the quarter ended June 30, 2026.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references an attached press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2) where the actual figures are located.
- Revenue, Profit, Cash Flow, Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of an earnings announcement for the quarter ended June 30, 2026.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company released a corporate presentation on August 4, 2026, available on its website (Exhibit 99.2).
Guidance and Risks: The filing text does not contain specific guidance, outlook, risk factors, or contingencies. These details are contained within the referenced exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter ended June 30, 2026.
- Examine Exhibit 99.2 (Earnings Presentation) for management's outlook, forward-looking guidance, and strategic updates.
- Verify year-over-year and quarter-over-quarter performance metrics in the attached exhibits, as they are not listed in the 8-K cover sheet.
- Confirm the status of the company's liquidity and debt obligations in the full financial statements referenced by the press release.